Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837667 | 0.87 | MEN1 (0.61) | GPR119MEN1KMT2AUSP30CCR5 | |
| SCHEMBL1307415 | 0.85 | GPR119 (0.60) | GPR119MEN1KMT2AUSP30 | |
| SCHEMBL4390067 | 0.83 | CCR5 (0.51) | CCR5 | |
| SCHEMBL4039291 | 0.83 | GPR119 (0.57) | GPR119USP30 | |
| SCHEMBL18263728 | 0.81 | MEN1 (0.72) | GPR119MEN1KMT2AUSP30 | |
| SCHEMBL3841257 | 0.81 | CCR5 (0.61) | GPR119MEN1KMT2AUSP30CCR5 | |
| SCHEMBL18263756 | 0.81 | MEN1 (0.60) | GPR119MEN1KMT2AUSP30 | |
| SCHEMBL3842743 | 0.81 | MEN1 (0.57) | GPR119MEN1KMT2AUSP30 | |
| SCHEMBL23253200 | 0.81 | GPR119 (0.54) | GPR119MEN1KMT2AUSP30 | |
| SCHEMBL30423390 | 0.79 | GPR119 (0.50) | GPR119MEN1KMT2AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551827-B1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | NOVARTIS AG | 2008-10-09 | — | — | US | disclosed |
| US-7399771-B2 | Piperidine derivatives as CCR5 inhibitors | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
| US-20060004047-A1 | Piperidine derivatives as ccr5 inhibitors | NOVARTIS AG (CH) | 2006-01-05 | — | — | US | disclosed |
| EP-1551827-A1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | Novartis AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031172-A1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | NOVARTIS AG (CH) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004047-A1 | Piperidine derivatives as ccr5 inhibitors | CCR5, CCR2, CCR1 | GPR119 167/4885MEN1 4636/4885KMT2A 4164/4885 |
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | CCR5, CCR2, CCR1 | GPR119 101/4885MEN1 4473/4885KMT2A 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.